Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial InfarctionJmjd3 controls mesodermal and cardiovascular differentiation of embryonic stem cellsHDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cellsClass IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactinEndpoints in stem cell trials in ischemic heart failureOxidative stress and epigenetic regulation in ageing and age-related diseasesMicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in miceMembers of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cellsRegulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylationAngiotensin II-induced upregulation of MAP kinase phosphatase-3 mRNA levels mediates endothelial cell apoptosisTransplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theRole of Dicer and Drosha for endothelial microRNA expression and angiogenesisNon-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cellsJumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemiaAtheroprotective communication between endothelial cells and smooth muscle cells through miRNAsTranscoronary transplantation of progenitor cells after myocardial infarction.CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia.Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction.Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial.Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells.Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease.Transplantation of progenitor cells after reperfused acute myocardial infarction: evaluation of perfusion and myocardial viability with FDG-PET and thallium SPECT.Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload.Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy.Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction.Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells anTelomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction.Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia.Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched ProgenitWnt5a increases cardiac gene expressions of cultured human circulating progenitor cells via a PKC delta activationIntracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial inA pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regRed blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy.Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis.Unchain my heart: the scientific foundations of cardiac repairQuantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
P50
Q22250889-99615370-DE70-49EB-B1BB-62CA4E9E9080Q24308177-87755662-4336-496C-A50A-5DDBD0769DD4Q24314211-13430E67-89A1-4AE7-B9AA-9D7AA0ACE850Q24322940-DCCFEEBC-B7BA-4A8A-B02D-0AF4DD7C3A2AQ26796330-DF284B26-128E-4383-ABA8-4D0965FFF310Q26991587-3E646549-64FF-4109-BA8C-D87C53A2D34FQ28115423-AEF3B0B8-9387-4246-A747-49A11727F471Q28115799-195957C1-C7A9-4E40-BB5B-E0DF91809A92Q28209368-AAD1CF10-32CB-4942-98B2-DEC9248C995EQ28216962-B25DDFB2-8E44-4F6D-B1E2-8F9DC5D2B91AQ28216990-1AE707D6-8FBC-4A3D-B8A1-084498CABB9EQ28267062-D42B96DA-9493-441B-8724-96A54824541DQ28304607-E596D97B-58CE-43BA-9D83-A29B66159906Q28306609-8B544BC3-0894-4BB5-BDCA-457D59023CCEQ28507470-D830C1A0-5DDF-47FB-ADF5-2ADB57F9D8B7Q28582868-10E4C848-2301-4B50-91E8-980D09C39DA7Q28941769-5E96667C-74E4-418E-B842-9CE43EEF1543Q30824315-37C950B4-6F43-47A5-8D05-992DF384E871Q30872414-D18DC97C-D32D-4005-8484-EA40979C823FQ30968626-0ACC4A6C-844B-4F66-9F4C-76AAF127D125Q33151955-AFB66E76-5D28-4D76-8B86-FB1552224179Q33194273-F66D0E29-B298-4589-BD2F-B3E5362A6C11Q33200016-9FB2C23F-E94B-4925-A0A9-D65ED902068DQ33200975-95F66C78-C3A7-4C58-AA81-49E327D7A1DFQ33215759-FCE9AE3B-4409-4255-B0F5-0B9151A3311CQ33257976-6FD9D9DB-EC2C-4E65-BB25-0EC3013A7BEDQ33263365-3841F6A2-0C2A-435D-B57A-36DCC4F63976Q33266079-08DBE7DB-4C9C-4ACB-BE6C-0AF0B2D8392CQ33273736-EB5E4BEF-1136-4202-B26D-304092EEEC91Q33290353-7604B5D0-90C6-459F-AC8A-27506F2647D7Q33319949-A0E0B644-3593-4289-A4A0-494B195C5BC0Q33408071-95F109F5-8E7E-4991-A07E-3FDF1AE1D0ABQ33413306-BA7A6254-605E-46D2-A688-86B831A49CD0Q33459175-AB64FDD6-A6BF-4E3F-B7FE-51C8A61D091FQ33507496-8880B8A2-9D49-47C8-849C-D3E348D968D1Q33508959-CB715322-2859-4C83-93D6-9DC2267B4F12Q33546217-B3837D5D-51D9-4D00-BE4D-88BE628B495CQ33633882-596C7BF7-8BAD-4451-B944-6AFE059723EFQ33683767-E91F726B-595D-4691-815F-8ACF381330CCQ33745065-2DBD123B-A744-45F9-9CA7-C5DC65217EAE
P50
description
Duits cardioloog
@nl
German cardiologist
@en
cardiólogu alemán
@ast
deutscher Mediziner
@de
médecin allemand
@fr
name
Andreas Zeiher
@ast
Andreas Zeiher
@ca
Andreas Zeiher
@da
Andreas Zeiher
@de
Andreas Zeiher
@en
Andreas Zeiher
@es
Andreas Zeiher
@fr
Andreas Zeiher
@it
Andreas Zeiher
@nb
Andreas Zeiher
@nl
type
label
Andreas Zeiher
@ast
Andreas Zeiher
@ca
Andreas Zeiher
@da
Andreas Zeiher
@de
Andreas Zeiher
@en
Andreas Zeiher
@es
Andreas Zeiher
@fr
Andreas Zeiher
@it
Andreas Zeiher
@nb
Andreas Zeiher
@nl
prefLabel
Andreas Zeiher
@ast
Andreas Zeiher
@ca
Andreas Zeiher
@da
Andreas Zeiher
@de
Andreas Zeiher
@en
Andreas Zeiher
@es
Andreas Zeiher
@fr
Andreas Zeiher
@it
Andreas Zeiher
@nb
Andreas Zeiher
@nl
P214
P227
P244
P106
P21
P213
0000 0000 3684 4505
P214
P227
1182486118
P244
n2005047865
P31
P5008
P569
1955-01-01T00:00:00Z
P734
P735
P7859
lccn-n2005047865